Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis

Phase 1

Not yet recruiting

Conditions: Lupus Nephritis (LN)

Interventions: Drug: Vonsetamig

First Posted Date: 2025-05-16

Last Posted Date: 2025-05-16

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 72

Registration Number: NCT06975787

Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women

Phase 1

Not yet recruiting

Conditions: Obesity

Interventions: Drug: Garetosmab
Drug: Matching Placebo

First Posted Date: 2025-05-14

Last Posted Date: 2025-05-14

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT06970405

A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

Phase 2

Conditions: Melanoma

Interventions: Drug: Fianlimab+cemiplimab

First Posted Date: 2025-02-26

Last Posted Date: 2025-05-14

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT06848088

Locations: 🇺🇸
Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
🇺🇸
South Texas Oncology And Hematology, San Antonio, Texas, United States

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

Phase 1

Not yet recruiting

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease
Metabolic Dysfunction-Associated Steatohepatitis

Interventions: Drug: ALN-CIDEB
Drug: Placebo

First Posted Date: 2025-02-20

Last Posted Date: 2025-02-20

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT06836609

REGN5381 in Adult Participants With Uncontrolled Hypertension

Phase 2

Recruiting

Conditions: Uncontrolled Hypertension

Interventions: Drug: REGN5381
Drug: Placebo

First Posted Date: 2025-02-18

Last Posted Date: 2025-05-08

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 732

Registration Number: NCT06833190

Locations: 🇬🇧
Protas, Car Park of Asda Pilsworth Road, Bury, United Kingdom
🇬🇧
Protas, Car Park of Asda Huyton Supercentre, Huyton, Liverpool, United Kingdom
🇬🇧
Protas, Two New Bailey Square, Salford, Manchester, United Kingdom